AcelRx reports positive trial results for drug-device combo

05/22/2013 | Reuters

AcelRx Pharmaceuticals is on schedule to file for FDA marketing approval in the third quarter after its Sufentanil NanoTab PCA System reached its key goal in a late-stage study. The 426-participant trial showed that compared with a placebo, the drug-device combination reduced pain intensity for patients 48 hours after undergoing hip or knee replacement surgery.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT